An independent clinical trial site owner is looking at a spreadsheet that says her practice has eleven weeks of payroll left.
She signed a contract with a mid-size sponsor four months ago. The trial is enrolling on schedule. The invoice for the last milestone went out fifty-three days ago and has not been paid, and nobody at the sponsor's finance office will tell her when it will be. This is not her first late payment from this particular relationship. It is her third, and each time the explanation has been some version of "processing," with no timeline attached.
She had no way to know, before she signed, that this sponsor's payment cycle would look like this. There was nothing in the feasibility questionnaire that asked about it, and nothing anywhere that would have told her, because no site anywhere keeps a record another site can see. Somewhere, another independent site is deciding right now whether to sign with this same sponsor, running the same blind calculation she ran four months ago.
Meanwhile, on the other side of this exact relationship, the sponsor's site-selection team chose her practice off a feasibility questionnaire that asked about her enrollment history and asked nothing about her cash reserves. They have no way to know that a two-month payment delay could be the difference between her finishing this study and her practice closing before it does, taking the patients already enrolled in it along with it.
Both sides are flying blind about exactly the thing that would let them price the actual risk they are entering into together.
Neither the site nor the sponsor can see the other's reliability before signing, and the industry has learned to treat the resulting closures and disputes as ordinary friction rather than as a solvable information failure.
Most sites are running on a trial pipeline too thin to absorb a shock
Start with how exposed the average site actually is, because the concentration is more extreme than "small business cash flow risk" usually implies.
Analysis of Open Payments-derived data by Glass and Guy, published in ACRP's Clinical Researcher in 2022, found that of roughly 37,600 US physician-investigators active in industry trials over a three-year window, 80 percent ran only 1 to 5 trials in that period. That is not a diversified revenue base. It is the profile of an operation dependent on a small, irregular pipeline of studies, each one a meaningful share of the practice's research income, with no cushion built from volume.
Layer the actual cost of activating and running a site on top of that concentration. Tufts CSDD data, compiled across recent industry reporting, puts site activation costs at roughly $20,000 to $25,000 and Phase III direct trial costs at approximately $55,716 per day. A site carrying that fixed-cost structure on a thin, undiversified pipeline is exactly the kind of operation a payment delay of even a few weeks can meaningfully destabilize.
And the exposure window keeps getting longer, not shorter. IQVIA's Global Trends in R&D data shows enrollment duration lengthened from 14.9 to 16.3 months between 2024 and 2025 alone. Every added month of enrollment is an added month a site's fixed costs run against a payment cycle it does not control and cannot see in advance.
The payment problem is real, named, and still unmatched with a fix
This is not a new complaint the industry has ignored. It is a documented, actively litigated grievance that has never produced the actual fix.
The Society for Clinical Research Sites runs a standing Payment Initiative that names, explicitly, holdback payments, taxation on participant reimbursements, and delayed payment frequencies as active, unresolved financial burdens on sites. That an industry advocacy body has a named, ongoing campaign around this exact issue confirms the problem is recognized industry-wide. It has been treated, so far, as an advocacy and negotiation issue rather than as an information-disclosure problem, and that framing has not produced a fix, because advocacy changes norms slowly and unevenly, while a disclosed track record would let a site avoid a bad counterparty before signing at all.
It is worth being honest here about the limits of the publicly available evidence, because some of the most commonly cited figures in this space have not held up to scrutiny. Claims circulating in industry discussion that roughly 80 percent of sites hold under six months of operating capital, and that 45 to 60 percent of new sites close after a single study, could not be traced to a verifiable primary SCRS or Milken Institute publication in this research. Those specific numbers should be treated as unverified pending direct access to underlying survey data, even though the general direction, that independent sites operate with thin margins and real closure risk, is well supported by the investigator-concentration and cost data above.
Why this is rational non-disclosure, not an oversight
The instinct is to ask why nobody has simply published this information already. The answer is that neither party benefits from disclosing first, and that is not a coincidence, it is the predictable result of how the incentives sit.
A sponsor does not want a public record of its own slow-pay behavior circulating among the site pool it needs for its next study. A site does not want to advertise thin cash reserves to a counterparty it is actively trying to win business from. Both financial reputations, the sponsor's payment reliability and the site's solvency, are exactly the kind of information a rational counterparty would want disclosed before signing a contract, and exactly the kind neither party will disclose voluntarily on its own.
That is not a market failure anyone forgot to fix. It is two parties behaving rationally in the absence of a neutral third party who can hold both disclosures without being captured by either side's commercial interest.
The missing primitive is a two-sided, verified financial-trust graph
What is actually absent is not information. Sites individually know exactly how a given sponsor paid them. Sponsors individually know exactly which sites they have worked with successfully. What is absent is the aggregation and verification layer: sites reporting sponsor payment behavior confidentially to other verified sites, and a parallel, verified signal of site financial durability that a sponsor could use in feasibility scoring, both assembled by a party neither side controls.
Neither side can build this alone. A single site publishing its own experience with a sponsor exposes that site to retaliation risk on its next contract. A sponsor voluntarily publishing its own payment record has no reason to, since silence costs it nothing today. Only a neutral, membership-gated structure, one that reports to neither a sponsor's finance department nor a site network's own investors, can credibly hold both sides of this ledger and make individual disclosure safe through aggregation.
Why the obvious builders have not built it
CROs and site-network aggregators solve this only for the sites they own outright. Organizations like Javara, Velocity Clinical Research, Alcanza, and Headlands Research internalize this exact risk by acquiring independent sites and absorbing the payment-cycle exposure at the corporate level. That is a real solution for the sites inside those networks. It structurally excludes the independent sites, the ones running on the thinnest pipelines, who are most exposed to the risk in the first place and least able to buy their way into a network's protection.
SCRS advocates industry-wide but has not built a sponsor-specific registry. Its Payment Initiative names the problem accurately and consistently. Building a site-facing, sponsor-specific payment-reliability registry would put the organization in direct tension with the sponsors and CROs who fund much of the clinical trials industry's conference and advocacy ecosystem, which is likely why the advocacy has stayed at the level of naming the issue rather than publishing comparative data.
Sponsors' finance and vendor-management functions have no incentive to make payment behavior comparable across the industry. There is no regulatory or competitive pressure pushing a sponsor to make its own invoice-to-payment timeline benchmarkable against its competitors, and plenty of reason not to.
What would actually work
A confidential, aggregated site-reported sponsor payment ledger. Verified sites report actual payment timelines, holdback terms, and dispute history by sponsor, into a system where individual reports are protected by aggregation across enough independent reporters that no single site's report is attributable.
A parallel, opt-in site durability signal for sponsors. Sites that choose to disclose financial stability indicators gain a credibility advantage in feasibility scoring, while retaining full control over whether and what they disclose, keeping this asymmetric protection intentional rather than accidental.
Enough independent reporters per sponsor before publishing anything. A useful payment record needs multiple, independent site reports on the same sponsor before it can be shown without risking the identity of any single reporter; a thin dataset protects nobody and should not be published prematurely.
A neutral, dues-funded structure with no sponsor or CRO revenue dependency. The credibility of the entire system rests on the holder having no commercial reason to soften an unflattering payment record, which rules out anything funded by the sponsors and CROs being scored.
Legal clarity on what a site can disclose. Confidentiality clauses inside individual site-sponsor contracts, and antitrust considerations around sites collectively sharing sponsor-specific data, need to be mapped explicitly rather than assumed away, so participating sites are not exposed to legal risk for reporting honestly.
A recruiting incentive for sponsors with genuinely strong records. A sponsor with a verifiably fast, reliable payment history should be able to have that record confirmed and displayed as a competitive advantage in recruiting hesitant new sites, turning transparency into a positive-sum signal rather than a purely defensive one.
What you can do now
If you run or manage a clinical trial site
Start your own private payment-timeline log today, sponsor by sponsor. Actual invoice date versus actual payment date, and any holdback or dispute history. This costs nothing to start and becomes valuable the moment any shared system exists to contribute it to.
Ask about payment terms as explicitly as you ask about protocol design before signing. Days-to-payment, holdback percentage, and dispute-resolution process belong in the same due-diligence conversation as enrollment target and visit schedule, not left for the first invoice to reveal.
Talk to peer sites informally about specific sponsors before you sign, even without a formal system. The SCRS Site Solutions Summit community and forums like r/ClinicalResearch are, right now, the closest thing to the missing registry; use them deliberately rather than treating payment reliability as something you only discover after the fact.
If you select or manage sites as a sponsor or CRO
Add a financial-durability question to your feasibility questionnaire. Enrollment history is not the only variable that predicts whether a site finishes a study; asking about reserves, pipeline diversification, or recent payment disputes with other sponsors costs one additional question and surfaces a real risk factor current questionnaires ignore entirely.
Audit your own payment cycle against your contracted terms. If your organization has a reputation problem with independent sites, you will not learn about it from the sites themselves, since disclosing dissatisfaction to the counterparty they depend on is exactly the risk this article describes; audit internally instead of waiting to be told.
Consider what a faster, verifiable payment cycle is worth as a recruiting asset. If your organization already pays reliably, an independently verified record of that fact is a real advantage in persuading a hesitant, thinly capitalized independent site to sign with you over a competitor.
If you fund or build clinical research infrastructure
Build the aggregation layer before the product layer. The hard, valuable part of this problem is establishing a trustworthy, sufficiently anonymous reporting threshold, not the interface that displays the resulting index.
Resolve the legal questions before launch, not after. Confidentiality-clause conflicts and antitrust exposure for collective site disclosure are real, foreseeable risks that need a clear answer before sites can be asked to participate honestly.
Frequently asked questions
How often are clinical trial sites paid late by sponsors? Precise industry-wide figures are not publicly available, but the Society for Clinical Research Sites runs a standing Payment Initiative naming holdback payments, participant-reimbursement taxation, and delayed payment frequencies as active, unresolved burdens, confirming the problem is recognized and persistent industry-wide even without a single definitive rate.
Why do clinical trial sites go out of business? The most defensible evidence points to thin, undiversified trial pipelines rather than enrollment failure alone: Glass and Guy's 2022 ACRP analysis found 80 percent of roughly 37,600 active US physician-investigators ran only 1 to 5 trials over a three-year window, meaning most sites carry high fixed research costs against a small, irregular revenue base with little room to absorb a payment shock. Widely circulated claims about specific site-closure rates after a single study could not be independently verified and should be treated with caution.
What is a payment holdback in a clinical trial contract? A holdback is a contractual arrangement where a sponsor withholds a portion of a site's invoiced payment, often until a study milestone or closeout requirement is met. SCRS's Payment Initiative names holdback payments specifically as one of the recurring financial burdens sites report, alongside delayed payment frequency and taxation on participant reimbursements.
How can a site check a sponsor's payment history before signing a contract? Currently, there is no formal registry or database a site can consult. Sites rely on informal word of mouth, personal networks, and community forums such as the SCRS Site Solutions Summit or r/ClinicalResearch, since no neutral, verified, cross-sponsor payment-reliability record currently exists.
Do larger site networks solve this payment-reliability problem? Only for the sites inside them. CRO-affiliated and aggregator-owned site networks such as Javara, Velocity Clinical Research, Alcanza, and Headlands Research absorb payment-cycle risk at the corporate level for owned sites, which structurally leaves independent sites, the ones on the thinnest pipelines per the Glass and Guy data, without an equivalent protection.
What would fix the two-sided opacity between sponsors and sites? A neutral, verified ledger where sites confidentially report sponsor payment timelines in aggregate, protecting individual reporters, paired with an opt-in signal sites could use to demonstrate financial durability to sponsors during feasibility scoring. No current SCRS, CRO, or sponsor-run system provides this, largely because a credible version requires a party funded by neither sponsors nor site networks.
The bottom line
Eighty percent of active US physician-investigators are running one to five trials over three years, a pipeline too thin to absorb a shock, against fixed site-activation and per-day trial costs in the tens of thousands. Enrollment windows keep stretching, extending every site's exposure to a payment cycle it cannot see coming. The industry's own advocacy body has named the payment problem explicitly and repeatedly, without producing the registry that would actually fix it.
This is not a case of missing information. Every site already knows exactly how its own sponsors have paid it. Every sponsor already knows exactly which sites finished their studies and which did not. What is missing is the aggregation layer that would let either side see the pattern before signing, rather than discovering it invoice by invoice, months into a study that both parties are now stuck inside together.
Both sides are behaving rationally by staying silent. Neither wants to disclose first. That is precisely the condition a neutral, verified, membership-gated ledger exists to solve, and precisely why nobody currently positioned to build one, CRO, sponsor, or advocacy body, has an incentive to be the one who does.
The site owner staring at eleven weeks of payroll signed a contract with no way to know what she now knows. Somewhere, another site is about to sign the same contract, blind in exactly the same way.
Part of a series on the missing professional infrastructure of healthcare. Previously: Who Else Is Treating This Patient? The Cross-Institution Coordination Gap
Evidence note: investigator concentration figures (80 percent of roughly 37,600 physician-investigators running 1 to 5 trials in a three-year window) come from Glass HE and Guy R, ACRP Clinical Researcher, 2022, an analysis of Open Payments-derived data. Site activation cost and per-day Phase III trial cost figures are compiled Tufts CSDD estimates reported through Applied Clinical Trials and IntuitionLabs industry coverage. Enrollment duration figures (14.9 to 16.3 months) are from IQVIA's Global Trends in R&D. The SCRS Payment Initiative description reflects that organization's own published materials as of the most recent access. Commonly circulated figures claiming roughly 80 percent of sites hold under six months of operating capital and that 45 to 60 percent of new sites close after a single study could not be traced to a verifiable primary SCRS or Milken Institute source in this research and are explicitly flagged here as unverified rather than presented as established fact. This article addresses the two-sided financial-disclosure gap between sponsors and sites specifically, and is distinct from this series' separate coverage of site-selection search failure and one-and-done investigator re-discovery.
